Wall Street Analysts Initiate Coverage on Several Stocks with Bullish Notes

Analysts from HC Wainwright, DA Davidson, Raymond James, and Leerink Partners initiated coverage on various stocks with bullish ratings. Brandon Folkes initiated coverage on Indivior PLC with a Buy rating and a $28 price target, while Griffin Bryan initiated coverage on Almonty Industries Inc. with a Buy rating and a $7 price target. Douglas Tsao initiated coverage on Rapport Therapeutics, Inc. with a Buy rating and a $31 price target, and Ryan Deschner initiated coverage on Palvella Therapeutics, Inc. with an Outperform rating and a $54 price target. Daina Graybosch initiated coverage on Adagene Inc. with an Outperform rating and a $7 price target.

July 02, 2025

Analysts from prominent firms have initiated coverage on several health care stocks with bullish ratings. Among the stocks that have received analyst attention are Indivior PLC, Almonty Industries Inc., Rapport Therapeutics, Inc., Palvella Therapeutics, Inc., and Adagene Inc.

Brandon Folkes of HC Wainwright & Co. initiated coverage on Indivior PLC (INDV) with a Buy rating and a price target of $28. The analyst noted that the durability of Sublocade revenue in the growing long-acting injectable market for opioid use disorder is underappreciated, and Indivior’s operational focus could drive meaningful cost reduction efforts [1].

Griffin Bryan of DA Davidson initiated coverage on Almonty Industries Inc. (ALM) with a Buy rating and a price target of $7. The analyst highlighted the potential in the lithium market and Almonty’s strategic position [2].

Douglas Tsao of HC Wainwright & Co. initiated coverage on Rapport Therapeutics, Inc. (RAPP) with a Buy rating and a price target of $31. The analyst emphasized the company’s pipeline and potential for growth [2].

Ryan Deschner of Raymond James initiated coverage on Palvella Therapeutics, Inc. (PVLA) with an Outperform rating and a price target of $54. The analyst praised the company’s pipeline and market potential [2].

Daina Graybosch of Leerink Partners initiated coverage on Adagene Inc. (ADAG) with an Outperform rating and a price target of $7. The analyst highlighted the company’s potential in the gene therapy space [2].

These analyst ratings and price targets reflect a positive outlook on the growth prospects of these companies. Investors should carefully evaluate each company’s fundamentals and risks before making investment decisions.

References:
[1] https://www.tipranks.com/news/the-fly/indivior-initiated-with-a-buy-at-h-c-wainwright-thefly
[2] https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/46895670/this-palvella-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday